The looming patent cliff exposes a deeper industry challenge, as biopharma companies face up to $400 billion in at-risk revenue while struggling to translate abundant data into actionable insight needed to compete in increasingly crowded markets.
Janice MacLennan
Advertisement
Janice MacLennan is CEO of Nmblr, the Biopharma and MedTech collaborative strategy platform. With over 30 years’ experience helping Biopharma and Medical Device companies tackle complex commercial challenges and develop winning strategies, she brings deep industry insight and personal passion to her work. Janice has dedicated her career to supporting the delivery of breakthrough therapies through consultancy partnerships with big and mid-sized companies across the globe. At Nmblr, she leads efforts to humanize strategy - empowering teams to align, adapt, and move as one to make better decisions and ensure innovations are delivered successfully, and to a receptive market.
Articles by Janice MacLennan
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
GSK Enters Exclusive Collaboration with SBP Group to Accelerate Bepirovirsen at Launch in Mainland China
2
President Trump Planning to Fire FDA Commissioner Marty Makary: Report
3
Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen
4
FDA Extends Priority Review of Leqembi Iqlik Subcutaneous Injection
5